nitroprusside 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
4631 14402-89-2

Description:

MoleculeDescription

Synonyms:

  • sodium nitroprusside hydrate
  • sodium nitroprusside
  • nitroprussiat
  • nitroprusside sodium
  • nitroprusside sodium salt
  • sodium nitroferricyanide
  • sodium nitroprussiate
  • sodium nitrosylpentacyanoferrate
  • nitroprusside
Sodium nitroprusside interacts with oxyhemoglobin to produce methemoglobin, cyanide, and nitric oxide (NO). NO then reacts with guanylate cyclase in vascular smooth muscle to produce cGMP that reduces intracellular calcium concentrations resulting in relaxation of vascular smooth muscle and consequent dilatation of peripheral arteries and veins.
  • Molecular weight: 261.92
  • Formula: C5FeN6Na2O
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

DoseUnitRoute
50 mg P

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
May 10, 1974 FDA ROCHE
Aug. 25, 2021 PMDA MARUISHI PHARMACEUTICAL Co., Ltd

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Fear 53.48 41.92 16 648 9488 29564375
Injury 46.24 41.92 17 647 19029 29554834

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Fear 78.83 43.61 24 1060 20147 64477501
Renal failure 61.43 43.61 38 1046 181650 64315998
Anhedonia 60.83 43.61 18 1066 13688 64483960
Renal injury 58.73 43.61 18 1066 15411 64482237
Injury 58.20 43.61 25 1059 55967 64441681
Unevaluable event 57.31 43.61 24 1060 50465 64447183
Multiple organ dysfunction syndrome 49.59 43.61 27 1057 101386 64396262
Emotional distress 43.80 43.61 18 1066 36020 64461628

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC C02DD01 CARDIOVASCULAR SYSTEM
ANTIHYPERTENSIVES
ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON
Nitroferricyanide derivatives
FDA PE N0000009909 Vasodilation
MeSH PA D000959 Antihypertensive Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D007202 Indicators and Reagents
MeSH PA D020030 Nitric Oxide Donors
MeSH PA D014665 Vasodilator Agents
FDA EPC N0000175940 Vasodilator

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Hypertensive disorder indication 38341003 DOID:10763
Acute heart failure indication 56675007
Malignant essential hypertension indication 78975002 DOID:10823
Decompensated cardiac failure indication 195111005
Hypertensive urgency indication 443482000
Acute exacerbation of chronic congestive heart failure indication 698296002
Controlled Hypotension indication
Coarctation of aorta contraindication 7305005
Chronic obstructive lung disease contraindication 13645005 DOID:3083
Hypovolemia contraindication 28560003
Acute cerebrovascular insufficiency contraindication 29322000
Tobacco amblyopia contraindication 30483005
Hypothyroidism contraindication 40930008 DOID:1459
Acute nephropathy contraindication 58574008
Leber's optic atrophy contraindication 58610003 DOID:705
Benign intracranial hypertension contraindication 68267002 DOID:11459
Disorder of brain contraindication 81308009 DOID:936
Hyponatremia contraindication 89627008
Cobalamin deficiency contraindication 190634004
Disease of liver contraindication 235856003 DOID:409
Anemia contraindication 271737000 DOID:2355




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Soluble guanylate cyclase Enzyme ACTIVATOR CHEMBL CHEMBL
Atrial natriuretic peptide receptor 1 Enzyme WOMBAT-PK

External reference:

IDSource
D00614 KEGG_DRUG
4017812 VUID
N0000178982 NUI
13755-38-9 SECONDARY_CAS_RN
4017812 VANDF
CHEBI:7596 CHEBI
CHEMBL2097081 ChEMBL_ID
CHEMBL136478 ChEMBL_ID
DB00325 DRUGBANK_ID
169D1260KM UNII
11953895 PUBCHEM_CID
7476 RXNORM
1098 MMSL
5489 MMSL
NOCODE MMSL
d00136 MMSL
000664 NDDF
372860000 SNOMEDCT_US
387139005 SNOMEDCT_US
8163008 SNOMEDCT_US
D009599 MESH_DESCRIPTOR_UI
C0028193 UMLSCUI
15078-28-1 SECONDARY_CAS_RN

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Nitropress HUMAN PRESCRIPTION DRUG LABEL 1 0187-4302 INJECTION, SOLUTION, CONCENTRATE 50 mg INTRAVENOUS ANDA 19 sections
sodium nitroprusside HUMAN PRESCRIPTION DRUG LABEL 1 14789-012 INJECTION 25 mg INTRAVENOUS ANDA 21 sections
sodium nitroprusside HUMAN PRESCRIPTION DRUG LABEL 1 14789-012 INJECTION 25 mg INTRAVENOUS ANDA 21 sections
Sodium Nitroprusside HUMAN PRESCRIPTION DRUG LABEL 1 17478-014 INJECTION, SOLUTION, CONCENTRATE 50 mg INTRAVENOUS ANDA 22 sections
SODIUM NITROPRUSSIDE HUMAN PRESCRIPTION DRUG LABEL 1 25208-003 INJECTION, SOLUTION, CONCENTRATE 25 mg INTRAVENOUS ANDA 15 sections
SODIUM NITROPRUSSIDE HUMAN PRESCRIPTION DRUG LABEL 1 42571-265 INJECTION 50 mg INTRAVENOUS ANDA 12 sections
Sodium Nitroprusside HUMAN PRESCRIPTION DRUG LABEL 1 43598-587 INJECTION, SOLUTION 50 mg INTRAVENOUS ANDA 20 sections
NIPRIDE RTU HUMAN PRESCRIPTION DRUG LABEL 1 51754-1006 INJECTION, SOLUTION 0.50 mg INTRAVENOUS NDA 17 sections
NIPRIDE RTU HUMAN PRESCRIPTION DRUG LABEL 1 51754-1018 INJECTION, SOLUTION 0.20 mg INTRAVENOUS NDA 17 sections
NIPRIDE RTU HUMAN PRESCRIPTION DRUG LABEL 1 51754-1029 INJECTION, SOLUTION 0.20 mg INTRAVENOUS NDA 17 sections
SODIUM NITROPRUSSIDE Human Prescription Drug Label 1 55150-320 INJECTION 50 mg INTRAVENOUS ANDA 12 sections
Sodium Nitroprusside Human Prescription Drug Label 1 65145-101 INJECTION 50 mg INTRAVENOUS ANDA 19 sections
Sodium nitroprusside HUMAN PRESCRIPTION DRUG LABEL 1 67457-839 INJECTION, SOLUTION, CONCENTRATE 25 mg INTRAVENOUS ANDA 19 sections
Sodium nitroprusside HUMAN PRESCRIPTION DRUG LABEL 1 67457-999 INJECTION, SOLUTION, CONCENTRATE 25 mg INTRAVENOUS ANDA 19 sections
SODIUM NITROPRUSSIDE HUMAN PRESCRIPTION DRUG LABEL 1 69097-532 INJECTION, SOLUTION, CONCENTRATE 50 mg INTRAVENOUS ANDA 12 sections
Sodium Nitroprusside HUMAN PRESCRIPTION DRUG LABEL 1 70069-261 INJECTION, SOLUTION, CONCENTRATE 25 mg INTRAVENOUS ANDA 17 sections
Sodium nitroprusside HUMAN PRESCRIPTION DRUG LABEL 1 70121-1189 INJECTION 25 mg INTRAVENOUS ANDA 18 sections
sodium nitroprusside HUMAN PRESCRIPTION DRUG LABEL 1 70436-028 INJECTION, SOLUTION, CONCENTRATE 50 mg INTRAVENOUS ANDA 19 sections
Sodium Nitroprusside HUMAN PRESCRIPTION DRUG LABEL 1 70700-126 INJECTION, SOLUTION, CONCENTRATE 50 mg INTRAVENOUS ANDA 13 sections
Sodium Nitroprusside HUMAN PRESCRIPTION DRUG LABEL 1 71288-202 INJECTION, SOLUTION 50 mg INTRAVENOUS ANDA 22 sections
Sodium Nitroprusside Human Prescription Drug Label 1 71839-120 INJECTION 50 mg INTRAVENOUS ANDA 19 sections
SODIUM NITROPRUSSIDE HUMAN PRESCRIPTION DRUG LABEL 1 72485-105 INJECTION 50 mg INTRAVENOUS ANDA 12 sections
SODIUM NITROPRUSSIDE HUMAN PRESCRIPTION DRUG LABEL 1 72485-305 INJECTION 50 mg INTRAVENOUS ANDA 13 sections